Recommendations for the Management of Special Populations: Racial and Ethnic Populations

American Journal of Hypertension

Volumn 16, Issue 11 II, 2003, Pages

  Ferdinand, Keith C ^a,b  

^a XAVIER UNIVERSITY OF LOUISIANA   (United States)

^b Heartbeats Life Center   (United States)

Author keywords

African Americans; Antihypertensive agents; Blood pressure; Diuretics; Hypertension; Renin angiotensin system

Indexed keywords

AMLODIPINE; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ATENOLOL; CALCIUM CHANNEL BLOCKING AGENT; CHLORTALIDONE; CLONIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXAZOSIN; FUROSEMIDE; HYDRALAZINE; LISINOPRIL; LOSARTAN; METOPROLOL; MINOXIDIL; RAMIPRIL; RESERPINE;

BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CAUSE OF DEATH; CLINICAL TRIAL; CONFERENCE PAPER; ETHNIC DIFFERENCE; GLOMERULUS FILTRATION RATE; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; KIDNEY FAILURE; META ANALYSIS; PRIORITY JOURNAL; RACE DIFFERENCE; STROKE; SYSTOLIC BLOOD PRESSURE;

EID: 0344946133     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjhyper.2003.07.007     Document Type: Conference Paper

References (14)

1. Obisesan TO, Vargas CM, Gillum RF: Geographic variation in stroke risk in the United States. Region, urbanization, and hypertension in the Third National Health and Nutrition Examination Survey. Stroke 2000,31:19-25.
2. Burt VL, Whelton P, Roccella EJ, Brown C, Cutler JA, Higgins M, Horan MJ, Labarthe D: Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988-1991. Hypertension 1995;25:305-313.
3. Materson BJ, Reda DJ, Cushman WC, Massie BM, Freis ED, Kochar MS, Hamburger RJ, Fye C, Lakshman R, Gottdiener J, Ramirez EA, Henderson WG: Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. N Engl J Med 1993;328:914-921.
4. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981-2997.
5. Weinberger MH: Comparison of captopril and hydrochlorothiazide alone and in combination in mild to moderate essential hypertension. Br J Clin Pharmacol 1982;14(Suppl 2):127S-131S.
6. Veterans Administration Cooperative Study Group of Antihypertensive Agents: Racial differences in response to low-dose captopril are abolished by the addition of hydrochlorothiazide. Br J Clin Pharmacol 1982;14(Suppl 2):97S-101S.
7. Cushman WC, Ford CE, Cutler JA, Margolis KL, Davis BR, Grimm RH, Black HR, Hamilton BP, Holland J, Nwachuku C, Papademetriou V, Probstfield J, Wright JT Jr, Alderman MH, Weiss RJ, Piller L, Bettencourt J, Walsh SM, for the ALLHAT Collaborative Research Group: Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens 2002;4:393-405.
8. Lopes AA: Hypertension in black people: pathophysiology and therapeutic aspects. J Hum Hypertens 2002;16(Suppl 1):S11-S12.
9. Flegal KM, Carroll MD, Ogden CL, Johnson CL: Prevalence and trends in obesity among US adults, 1999-2000. JAMA 2002;288: 1723-1727.
10. Agodoa LY, Appel L, Bakris GL, Beck G, Bourgoignie J, Briggs JP, Charleston J, Cheek D, Cleveland W, Douglas JG, Douglas M, Dowie D, Faulkner M, Gabriel A, Gassman J, Greene T, Hall Y, Hebert L, Hiremath L, Jamerson K, Johnson CJ, Kopple J, Kusek J, Lash J, Lea J, Lewis JB, Lipkowitz M, Massry S, Middleton J, Miller ER 3rd, Norris K, O'Connor D, Ojo A, Phillips RA, Pogue V, Rahman M, Randall OS, Rostand S, Schulman G, Smith W, Thornley-Brown D, Tisher CC, Toto RD, Wright JT Jr, Xu S, for the African American Study of Kidney Disease and Hypertension (AASK) Study Group: Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA 2001;285:2719-2728.
11. Douglas JG, Bakris L, Epstein M, Ferdinand KC, Ferrario C, Flack JM, Jamerson KA, Jones WE, Haywood J, Maxey R, Ofili EO, Saunders E, Schiffrin EL, Sica DA, Sowers JR, Vidt DG, for the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks: Management of high blood pressure in African Americans: consensus statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks. Arch Intern Med 2003; 163:525-541.
12. Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhager WH, Bulpitt CJ, de Leeuw PW, Dollery CT, Fletcher AE, Forette F, Leonetti G. Nachev C, O'Brien ET, Rosenfeld J, Rodicio JL, Tuomilehto J, Zanchetti A: Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 1997;350:757-764.
13. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH. Nieminen MS, Omvik P, Oparil S, Wedel H, for the LIFE Study Group: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995-1003.
14. Ferdinand KC: Introduction: management of hypertension and cardiovascular risk factors in African Americans. J Clin Hypertens 2003;5(Suppl 1):3-4.